Fierce Biotech6 小时
Elevation drops sole clinical-stage ADC over poor phase 1 data, lays off 70% of staff
Elevation Oncology is ditching its sole clinical-stage asset in the wake of disappointing phase 1 data, leading the ...
MacroGenics Provides Update on Corporate Progress and 2024 Financial Results
Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPCInitiating ...